Skip to main content

Advertisement

SpringerLink
Log in

Detailed analysis of retinal morphology in patients with diabetic macular edema (DME) randomized to ranibizumab or triamcinolone treatment

  • Letter to the Editor
  • Published:
Graefe's Archive for Clinical and Experimental Ophthalmology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Karst SG, Lammer J, Mitsch C et al (2018) Detailed analysis of retinal morphology in patients with diabetic macular edema (DME) randomized to ranibizumab or triamcinolone treatment. Graefes Arch Clin Exp Ophthalmol 256(1):49–58. https://doi.org/10.1007/s00417-017-3828-1

    Article  CAS  PubMed  Google Scholar 

  2. Freund KB, Korobelnik JF, Deveny R et al (2015) Treat-and extend regimens with anti-VEGF agents in retinal diseases. Retina 35:1489–1506

    Article  CAS  PubMed  Google Scholar 

  3. Gover S, Murthy RK, Brar VS, Chalam KV (2009) Normative data for macular thickness by high-definition spectral-domain optical coherence tomography (Spectralis). Am J Ophthalmol 148:266–271

    Article  Google Scholar 

  4. Călugăru D, Călugăru M (2017) Aflibercept for diabetic macular edema in eyes previously treated with ranibizumab and/or bevacizumab may further improve macular thickness. Ophthalmic Surg Lasers Imaging Retina 48(7):528–529

    Article  PubMed  Google Scholar 

  5. Călugăru D, Călugăru M (2016) Conversion to aflibercept after prior anti-VEGF therapy for persistent diabetic macular edema. Am J Ophthalmol 168(2):290–291

    PubMed  Google Scholar 

  6. Călugăru D, Călugăru M (2016) Pro-permeability factors in diabetic macular edema; the diabetic macular edema treated with ozurdex trial. Am J Ophthalmol 170(l):244–245

    PubMed  Google Scholar 

  7. Călugăru D, Călugăru M (2017) Aflibercept in diabetic macular edema: evaluating efficacy as a primary and secondary therapeutic option. Eye 31(2):342

    Article  PubMed  Google Scholar 

  8. Călugăru D, Călugăru M (2017) Switching therapy from bevacizumab to aflibercept for the management of persistent diabetic macular edema. Graefes Arch Clin Exp Ophthalmol 255(7):1451–1452

    Article  PubMed  Google Scholar 

  9. Călugăru D, Călugăru M (2016) Long-term efficacy and safety of intravitreal dexamethasone implant for the treatment of diabetic macular edema. Eur J Ophthalmol 26(6):171–172

    Article  Google Scholar 

  10. Călugăru D, Călugăru M (2017) Real-world outcomes of ranibizumab treatment for diabetic macular edema in a United Kingdom National Health Service setting. Am J Ophthalmol 174(2):175–176

Download references

Acknowledgments/disclosure

All authors have completed and submitted the ICMJE form for disclosure of potential conflicts of interest. No financial disclosures. Both authors (D.C and M.C) were involved in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript.

The authors have full control over the primary data, and they agree to allow Graefe’s Archive for Clinical and Experimental Ophthalmology to review their data if requested.

Author information

Authors and Affiliations

  1. Department of Ophthalmology, University of Medicine, Cluj-Napoca, Romania

    Dan Călugăru & Mihai Călugăru

Authors
  1. Dan Călugăru
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mihai Călugăru
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mihai Călugăru.

Ethics declarations

Conflict of interest

All authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest (such as honoraria; educational grants; participation in speakers’ bureaus; membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent-licensing arrangements), or non-financial interest (such as personal or professional relationships, affiliations, knowledge, or beliefs) in the subject matter or materials discussed in this manuscript.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Călugăru, D., Călugăru, M. Detailed analysis of retinal morphology in patients with diabetic macular edema (DME) randomized to ranibizumab or triamcinolone treatment. Graefes Arch Clin Exp Ophthalmol 256, 1035–1037 (2018). https://doi.org/10.1007/s00417-018-3901-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00417-018-3901-4

Search

Navigation